Acetazolamide Market Is Booming Across the Globe Explored in Latest Research

Acetazolamide Market.jpg
Acetazolamide is carbonic anhydrase inhibitor, used in adjuvant treatment of chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma, epilepsy, edema due to congestive heart failure, drug-induced edema, and acute mountain sickness in climbers. Acetazolamide promotes acclimatization to altitude, increases bicarbonate secretion by the kidneys, induces metabolic acidosis, and stimulates ventilation. Furthermore, according to the BMJ Journal, September 2012, acetazolamide in doses of 250 mg, 500 mg, and 750 mg daily are more effective compared to placebo for preventing acute mountain sickness. In addition, acetazolamide 250 mg daily is the lowest effective dose to prevent acute mountain sickness.

Extended Application of Acetazolamide in Various Treatment Modalities is expected to Drive Market Growth during the Forecast Period

Acetazolamide is used to prevent high altitude illness in most people, which is characterized by headache, nausea, vomiting, and tiredness (often called acute mountain sickness), but may affect the brain or the lungs in different individuals. As per the study published in Cochrane Journal, in June 2017, acetazolamide is an effective and better treatment for the prevention of acute high altitude illness (HAI) in dosages of 250 to 750 mg/day, when compared to a placebo. Acetazolamide prevents acute mountain sickness and has fewer side effects than alternative drugs such as dexamethasone. According to BMJ journal, May 2018, prescribing acetazolamide for travel is an optional service and not included in the general practitioner’s contract in the U.K.

Inquire Here Before Purchase of Research Report @ https://www.coherentmarketinsights.com/insight/talk-to-analyst/2396

Increasing Prevalence of Glaucoma among Global Population is expected to Aid in Market Growth

Increasing prevalence of glaucoma and associated risk factors such as high myopia, diabetes, eye surgery or injury, high blood pressure, increased usage of corticosteroids, and family history of glaucoma among the global population are expected to offer conducive future growth for acetazolamide drug manufacturers. As a sustained release capsule of Acetazolamide taken a day, offers a substantial pressure-lowering effect that lasts at least 23 hours. Treatment with acetazolamide helps to reduce eye pressure, which aids in preventing eye damage. Acetazolamide works by blocking the action of an enzyme called carbonic anhydrase thereby, reducing the amount of fluid secreted in the front part of eye, thus lowering eye pressure. For instance, according to the study published in the Journal of Ophthalmology (2014), an estimated 64.3 million people (aged 40-80 years) in 2013, were affected with glaucoma, which would increase to 76.0 million in 2020, and 111.8 million in 2040.

According to the International Agency for the Prevention of Blindness, 2017, glaucoma is the second leading cause of blindness and leading cause of irreversible blindness worldwide. With primary angle closure glaucoma (PACG) being the most common in South-East Asia while primary open-angle glaucoma (POAG) is mostly found among white Caucasians and individuals of Africa.

Among region, Asia Pacific is expected to be conducive region for the acetazolamide market growth. This is mainly owing to growing healthcare infrastructures, high prevalence of glaucoma, and associated risk factors such as diabetes and high blood pressure cases among the population of the region. For instance, according to American Academy of Ophthalmology (AAO), November 2013, glaucoma is the most common cause of preventable, irreversible blindness worldwide, among which primary open-angle glaucoma (POAG) is responsible for 12.3% of blindness. Furthermore, according to same source, POAG’s prevalence is estimated to be the highest among the people of China, intermediate in Japan, and lower in Europe and India. Therefore, these driving factors are expected to propel growth of acetazolamide market in Asia Pacific.

Key players operating in the acetazolamide market include Teva Pharmaceutical Industries Ltd., Accord Healthcare Ltd. (Intas Pharmaceuticals Limited), Heritage Pharmaceuticals Inc., Nostrum Laboratories Inc., Novast Laboratories Ltd., Cadila Healthcare (Zydus Pharmaceuticals (USA) Inc.), Lannett Company, Inc., Strides Shasun Limited, and X-GEN Pharmaceuticals, Inc.

About Coherent Market Insights

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.


Contact Us

Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702

Comments

Post a Comment

Popular posts from this blog

Breast Pumps Market Surge in Demand from Healthcare Industry to Boost Growth Forecast to 2026

Image
Breast pump devices enable women to express breast milk and store it for later use. These are especially useful for working mothers nursing a newborn. Breast pumps gaining eligibility for reimbursement under the Affordable Care Act is a key trend promoting its adoption in the U.S. Working mothers usually prefer automatic electronic breast pumps. These automatic breast pumps have adjustable suction level and variable cycling time, which offers enhanced comfort to the use. Double pumps help reduce pumping time as they drain both breasts simultaneously and more effectively. Market Dynamics Increasing awareness and favorable reimbursement policies are augmenting market growth. Growing number of women in the workforce is a major factor driving demand for breast pumps. Electric breast pumps which can express more milk in a shorter time are most popular among consumers in developed economies such as the U.S. and countries in Western Europe. However, the device is not...
Read more

Booms and Busts in Anatomic Pathology Market; Dynamics Trends Over The Time Discussed 2018-2026

Image
Anatomic pathology involves direct visualization of human tissue as gross examination as well as under a microscope for proper diagnosis of the disease or a pathological condition. Subtypes of anatomic pathology include surgical pathology, oral and maxillofacial pathology, cytopathology, molecular pathology, and forensic pathology. Procedures performed in anatomic pathology include gross examination, histopathology, immunohistochemistry, in situ hybridization, cryopathology, tissue cytogenetics, and others. Standard approach in anatomical pathology is microscopic examination of tissue samples with the help of one or more stains. Manufacturers have developed stains to identify and classify microorganisms in biopsy of tissue samples or excisional specimens. Various gram stains and acid-fast stains have applications in detection of bacteria and mycobacteria in tissue samples. Commercially available products include tissue processing systems, microtomes, cryostats, ...
Read more

Negative Pressure Wound Therapy (NPWT) Devices Market Outlook and Opportunities in Grooming Regions 2026

Image
Treatment options for wounds includes application of topical medication, sutures, staples, adhesives, compression therapy, hyperbaric oxygen therapy, biological dressings, and negative pressure wound therapy (NPWT). Negative pressure wound therapy, also called vacuum-assisted wound closure, has gained significant traction over the last decade as it is equally effective in acute and chronic wounds. NPWT is a relatively non-invasive wound therapy and offers various pips other conventional treatment options by facilitating better healing, shorter hospital stay, and fewer wound infections. Get Exclusive Sample Report at: http://bit.ly/30lpsDC Market Dynamics The primary benefits of NPWT such as elimination of edema, providing a moist wound-healing environment, and stimulating angiogenesis and blood flow to the wound is increasing its uptake. Moreover, the new guidelines outlined by the World Health Organization (WHO) in November 2016, recommends use of NPWT in...
Read more